Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer.
Klauck PJ, Bagby SM, Capasso A, Bradshaw-Pierce EL, Selby HM, Spreafico A, Tentler JJ, Tan AC, Kim J, Arcaroli JJ, Purkey A, Messersmith WA, Kuida K, Eckhardt SG, Pitts TM.
Klauck PJ, et al. Among authors: tan ac.
BMC Cancer. 2018 Feb 5;18(1):136. doi: 10.1186/s12885-018-4036-z.
BMC Cancer. 2018.
PMID: 29402316
Free PMC article.